STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer

May 29-June 2, 2015; Chicago, Illinois
Interesting results of a large randomized, multiarm, multistage trial that indicate a potential change in standard of care.
Format: Microsoft PowerPoint (.ppt)
File Size: 592 KB
Released: June 5, 2015

Acknowledgements

Educational grant provided by:
AstraZeneca
Bayer Healthcare Pharmaceuticals, Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Related Content

In this commentary from Clinical Care Options (CCO), Alexander Drilon, MD, discusses best practices in the use of TRK inhibitor therapy

person default Alexander Drilon, MD Released: July 10, 2020

In this slideset from Clinical Care Options, Scot Niglio, MD provides insights on the latest data on immunotherapy approaches for bladder cancer, RCC, and prostate cancer.

Scot Niglio, MD Released: July 9, 2020

Downloadable slideset from Celestia S. Higano, MD, FACP: How PARP inhibition works and the role of DDR genes and testing in prostate cancer, from CCO

Celestia Higano Headshot Celestia S. Higano, MD, FACP Released: July 9, 2020

Downloadable slideset from Charles J. Ryan, MD: Role of PARP inhibitors for the treatment of prostate cancer, from CCO

Celestia Higano Headshot Celestia S. Higano, MD, FACP Charles J. Ryan, MD Released: July 9, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?